1Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA, 2007, 104:18654-18659.
2Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology, 2007, 50:113-130.
3Soreide K, Nedrebo BS, Knapp JC, et al. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg Oncol, 2009, 18: 31-50.
4Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 1990, 61 : 759-767.
5Soreide K. Telomerase and survivin in colorectal and pancreatic cancer biomarkers of life and death in the balance between proliferation and apoptosis. Curr Cancer Ther Rev, 2008, 4:253-261.
6Soreide K, Thorsen K. Colorectal cancer - increased understanding of the multidimensional molecular genesis. Curr Cancer Ther Rev, 2008, 4: 243-252.
7Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten ras, and p53 alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA, 2002, 99: 9433-9438.
8Leslie A, Pratt NR, Gillespie K, et al. Mutations of APC, Kras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res, 2003, 63: 4656-4661.
9Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut, 2005, 54:1283-1286.
10Soreide K, Gudlaugsson E, Skaland I, et al. Metachronous cancer development in patients with sporadic colorectal adeno masmultivariate risk model with independent and combined value of hTERT and survivin. Int J Colorectal Dis, 2008, 23: 389-400.
4Greider CW, Blackburn EH. The telomere terminal trangferase of Teerahymena is a ribonacleoprotien enzyme with two kinds of pri- men specifictg. Cell, 1987,51:887-898.
5Hiyama E, Hiyama K. Telomerase detection in the diagnosis and prognosis of cancer. Cytotechnology, 2004,45:61-74.
